Link to this page

Your search term(s) "Erectile Dysfunction" returned 25 results.

Page 1 2 3    Display All

Male Sexual Dysfunction. IN: Tanagho, E.; McAninch, J., eds. Smith’s General Urology. 17th ed. Columbus, OH: McGraw Hill. 2008. pp 589-610.

This chapter about male sexual dysfunction is from an updated edition of a comprehensive textbook about urology that offers an overview of the diagnosis and treatment of diseases and disorders common to the genitourinary tract. The authors note that advances in pharmacologic therapy for erectile dysfunction (ED), coupled with a better understanding of male sexual dysfunction achieved through research on the mechanism, neurophysiology, and pharmacology of penile erection, have resulted in greater numbers of patients seeking primary and specialty care for sexual concerns. Erectile function can now be evaluated by response to oral drug agents at home or intracavernous injection of vasoactive agents in the office, and improved diagnostic tests can differentiate among types of impotence. Topics covered include the physiology of penile erection, innervation of the penis, anatomy and hemodynamics of penile erection, the mechanism of penile erection, hormones and sexual function, neurotransmitters and pharmacology of erection, the molecular mechanism of smooth-muscle contraction and relaxation, signal transduction in penile erection, the epidemiology of male sexual dysfunction, the classification of ED, diagnosis and treatment, advanced testing for ED, the nonsurgical treatment of ED, penile vascular surgery, penile prosthesis, and male sexual dysfunction involving emission, ejaculation, and orgasm. The chapter is illustrated with black-and-white drawings and photographs. The chapter concludes with an extensive list of references, categorized by topic. 6 figures. 6 tables. 77 references.

Full Record   Printer Friendly Version

Erectile Dysfunction and Peyronie's Disease. IN: Litwin, M.S.; Saigal, C.S., eds. Urologic Diseases in America. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse. pp. 483-530.

Male sexual health has taken on increased importance as the United States population ages, develops co-existing medical conditions, and undergoes interventions that can affect sexual health. This chapter focuses on two major areas of male sexual health, erectile dysfunction (ED) and Peyronie’s disease (PD). The chapter is from a lengthy text that offers a comprehensive portrait of the illness burden and resource use associated with the major urologic diseases in the United States. For each condition, the authors discuss definition and diagnosis; prevalence and incidence; risk factors; clinical evaluation; trends in health care resource utilization for this condition, specifically inpatient and outpatient care; emergency room care and surgical trends; and economic impact. The section on ED also considers the pharmacologic management of ED. A final section offers recommendations on the topic of diagnosis, treatment, and areas of needed research. The authors conclude that the treatments used for ED, as measured by hospital outpatient, ambulatory surgery, physician office visits, and cost reimbursement data, suggest shifting forms of health care utilization. Available data on PD is limited and it is difficult to assess accurately the true prevalence and impact of PD. 3 figures. 36 tables. 36 references.

Full Record   Printer Friendly Version

Erection Problems: What Men Need to Know. Los Problemas de Ereccion: Lo Que Los Hombres Deben Saber. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse. 2007. 4 p.

This fact sheet provides information about erectile dysfunction. Written in a question-and-answer format, the fact sheet discusses the normal physiology of an erection, the possible causes of erectile dysfunction, and treatment options, including counseling, oral medications, injection, vacuum devices, and penile implants. The fact sheet refers readers to the National Kidney and Urologic Diseases Information Clearinghouse (NIKUDIC) for more information (www.kidney.niddk.nih.gov). Two pages of the fact sheet are in English and the same information is repeated in Spanish on the other two pages.

Full Record   Printer Friendly Version

Beyond Viagra: What are Your Options?. Mayo Clinic Health Letter. 24(1): 7. January 2006.

This brief newsletter article reviews the treatment options for erectile dysfunction (ED). The article begins with an overview of the causes of ED, which can include physical causes such as diabetes, high blood pressure, or cardiovascular conditions and other causes including low levels of sexual desire (libido) or relationship issues. Surgeries to treat certain cancers (including prostate cancer) or drug side effects can also affect erectile function. Treatment can include one of three oral medications: sildenafil (Viagra), vardenafil (Levitra), or tadalafil (Cialis). The author explains how each of these drugs works and how they differ from one another. A final section outlines some of the other, non-drug treatment options for ED, including injectable drugs, vacuum devices, hormone therapy, and penile implants. Readers are encouraged to work closely with their health care provider to find an ED treatment that works for their own individual situation.

Full Record   Printer Friendly Version

Drugs Used in the Treatment of Erectile Dysfunction. IN: Eardley, I., et al, eds. Drug Treatment in Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 39-61.

This chapter on drugs used in the treatment of erectile dysfunction (ED) is from a book that offers a comprehensive summary of the role of pharmacology in urology. An introductory section reviews the physiology of erection, the causes of ED, and the principles of drug therapy to improve erectile function. The chapter then covers specific drugs, including the orally active phosphodiesterase type 5 (PDE5) inhibitors sildenafil, tadalafil, and vardenafil; centrally acting agents, notably apomorphine; and other occasionally-used oral agents, including phentolamine, yohimbine, and trazodone. The author then discusses the use of intracavernosal and intraurethral alprostadil, testosterone therapy, and agents currently under development. The author concludes that the PDE5 inhibitors remain the first line of therapy for most men with ED. Injectables are indicated following failure of initial oral therapy. 1 figure. 9 tables. 68 references.

Full Record   Printer Friendly Version

Erectile Dysfunction and Peyronie’s Disease. IN: Kellogg Parsons, J.; James Wright, E., eds. Brady Urology Manual. New York, NY: Informa Healthcare USA. 2006. pp 51-62.

This chapter about erectile dysfunction (ED) and Peyronie’s disease is from a reference handbook that offers a comprehensive overview of urology, presented in outline and bulleted formats for ease of access in the busy health care world of hospital emergency rooms and outpatient clinics. The authors define ED as the consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual activity. They cover the different types of ED, epidemiology, physiology of erection, patient evaluation, and treatment options, including drug therapy, intracavernous injection therapy, intraurethral injection therapy, vacuum constriction devices, and penile prosthesis. The second section discusses Peyronie’s disease, a localized connective tissue disorder of the penis, characterized by changes in the collagen composition of the tunica albuginea. The authors discuss epidemiology, pathophysiology, presentation and evaluation, medical therapy, and surgical therapy. Peyronie’s disease typically presents as a palpable penile plaque, penile pain, penile curvature, and ED. Treatment includes medical therapy and surgery. The chapter concludes with a list of references for additional reading. 1 figure. 1 table. 49 references.

Full Record   Printer Friendly Version

Erectile Dysfunction: A Patient Quick-Guide to Cause, Diagnosis, and Treatment. Augusta, GA: Augusta Medical Systems. 2006. 22 p.

This booklet provides information on the causes and diagnoses of erectile dysfunction and on all currently-accepted therapies. Erectile dysfunction (ED) is defined as the repeated inability to achieve or sustain an erection sufficient for sexual intercourse. The authors review three factors that can lead to ED: psychological factors, ranging from depression to self-esteem issues; physical factors, which can include trauma (from surgery or injury) and diseases (diabetes, cardiovascular disease); and drug effects, including those from prescription, non-prescription, and recreational or illegal substances. These factors can interrupt the delicate process of mental, nervous, and vascular systems that must work together to produce an erection. One section of the booklet explains what to expect from the first physician visit, including commonly used diagnostic tests. The authors then discuss treatments, including psychotherapy, vacuum therapy systems, oral medications (sildenafil, vardenafil, tadalafil), self-injection, urethral suppositories, and penile implants. The authors also consider the side effects and costs of each of these treatment options. A final section describes the work of the American Urological Association and refers readers to the book-length version of this booklet, published in June 2006 (ISBN: 0-9868949-1-2). 16 figures. 2 tables. 14 references.

Full Record   Printer Friendly Version

Sexual Health. IN: Blueprint for Men's Health: A Guide to a Healthy Lifestyle. Washington, DC: Men's Health Network. June 2006. pp. 21-25.

This chapter on sexual health is from a booklet that reviews a wide spectrum of health issues, focusing on health promotion and prevention for men. In this chapter, the author discusses the most common sexual problems in men and how to manage them. Topics include erectile dysfunction (ED), safe sex and sexually transmitted diseases (STDs), birth control and contraception, and changes in sexuality with aging. The author reminds readers that one's overall health can have an impact on sexuality, so taking steps to improve overall health can help reduce or even eliminate problems such as ED. Readers are encouraged to talk with their health care provider about any concerns they may have in this area.

Full Record   Printer Friendly Version

Subfertility and Male Sexual Dysfunction. IN: Dawson, C.; Whitfield, H.N., eds. ABC of Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 18-21.

This chapter on subfertility and male sexual dysfunction is from an atlas of basic urologic problems that is designed to help general practitioners address the ever-increasing number of patients presenting to their offices with urological problems. Subfertility is defined as failure to conceive after regular unprotected sexual intercourse over a period of one year; this chapter only considers male subfertility. The author reviews the causes of male factor infertility and the diagnostic tests done to assess the condition. The author briefly discusses assisted reproductive techniques that can be used to treat couples affected by subfertility. The second section of the chapter covers erectile dysfunction (ED), its risk factors, symptoms, diagnosis, and treatment. Two brief final sections consider Peyronie disease and androgen decline in the aging male. The chapter features a few pages of text, summaries of information in charts and tables, a list of recommendations for further reading, and full-color photographs and illustrations. 7 figures. 8 tables. 4 references.

Full Record   Printer Friendly Version

Erectile Dysfunction and Other Urological Issues in the Transplant Patient. In: Medical Management of Kidney Transplantation. Philadelphia, PA: Lippincott Williams and Wilkins. 2005. pp. 449-472.

Genitourinary complications commonly affect the kidney transplant population. This chapter on erectile dysfunction (ED) and other urological issues in kidney transplant recipients is from a textbook on the medical management of kidney transplant patients. The authors discuss the epidemiology of ED, erectile anatomy and physiology, the etiology of ED in the transplant patient (vasculogenic, neurogenic, endocrinologic causes, as well as chronic disease), and the evaluation of ED in the transplant patient, including the history and physical, laboratory studies, the process of care model, endocrine evaluation, treatment of hypogonadism, psychiatric factors of sexual dysfunction, phosphodiesterase type 5 inhibitors, vacuum constriction devices, transurethral alprostadil, intracavernosal injection, and penile prostheses. The final sections consider preoperative urological issues, including indications for native nephrectomy and history of urological malignancy; and postoperative urological issues, including hematuria, hydronephrosis and obstruction, urinary tract infections, prostate cancer screening, urolithiasis (urinary tract stones), and bladder dysfunction. The authors conclude that a thorough understanding of the urological issues involved and the diagnostic and treatment options available enables an effective multidisciplinary approach to the transplant patient. 14 figures. 7 tables. 138 references.

Full Record   Printer Friendly Version

Page 1 2 3    Display All

Start a new search.